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Background: Fibromyalgia is a prevalent chronic rheumatic disease of great clinical importance. Recent studies
have found raised levels of glutamate in the insula, hippocampus and posterior cingulate cortex regions of the
brains of fibromyalgia (FM) patients. This finding has led researchers to speculate about the usefulness of
glutamate-blocking drugs such as memantine in the treatment of fibromyalgia. The hypothesis of this study is that
the administration of memantine will reduce the glutamate levels, and futhermore, will decrease the perceived
pain. The aim of this study is to evaluate the efficacy of memantine in the treatment of pain (pain perception). A
secondary objective is to evaluate the efficacy of memantine in the treatment of other clinical symptoms of FM,
and to evaluate the efficacy of memantine in reducing brain levels of glutamate, and its effects on the central
nervous system as a whole.
Method/Design: A double-blind parallel randomized controlled trial. Participants, Seventy patients diagnosed with
FM will be recruited from primary health care centers in Zaragoza, Spain. Intervention. The subjects will be
randomized in two groups: A) A treatment group (n = 35), which will receive 20 mg of memantine daily; B) A
control group (n = 35), to which will be administered a placebo. There will be a six-month follow-up period
(including a titration period of one month). Outcomes. The main efficacy variable of this study is pain (pain
perception). The secondary efficacy variables are clinical symptoms (pain threshold, cognitive function, health status,
anxiety, depression, clinical impression and quality of life) and glutamate levels in different regions of the brain,
which will be assessed by magnetic resonance spectroscopy. Randomization and blinding. Randomization has been
computer-generated, and the random allocation sequence will be implemented by telephone. Subjects of the
study and the research assistants will be blinded to group assignment.
Discussion: There is a need for the development of innovative and more effective treatments for fibromyalgia. This
clinical trial will determine whether memantine can be an effective pharmacological treatment for fibromyalgia
patients.
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Fibromyalgia (FM) is a chronic rheumatic disease of cur-
rently unknown aetiology that is characterized by the
presence of diffuse musculoskeletal pain and painful sen-
sitivity to touch in at least 11 of 18 defined trigger points
[1]. The prevalence of this syndrome in Europe is cal-
culated to be approximately 2.9% (95% CI: 2.4 to 3.4)
[2]. The prevalence of FM in rheumatology consultations
in Spain was found to be 12% (2.2% in men and 15.5%
in women) [3]. Because of its high prevalence, there is
great clinical impact on patients in terms of disability
and loss of quality of life, and significant health care
costs. FM treatments are believed to have limited effi-
cacy, with an effect size of approximately 0.5 [4].
Pain is the most common and debilitating symptom of
FM. The cause of hyperalgesia in FM is poorly under-
stood. It is suspected that there is an alteration of the
function of structures of the central nervous system. In
recent years, the neurophysiology of the phenomenon of
pain has led to increased interest in employing different
neuroimaging methods such as positron emission to-
mography (PET) [5], single photon emission computed
tomography (SPECT) [6,7], functional magnetic reso-
nance imaging (fMRI) and, more recently, magnetic re-
sonance diffusion and diffusion tensor spectroscopy to
identify the brain structures activated during episodes of
pain in patients and controls [8]. These structures
include the primary and secondary sensory and motor
cortices, insula, anterior cingulate cortex, thalamus,
dorsolateral prefrontal cortex and basal ganglia - regions
that have been named the ‘pain matrix’ because they are
activated in response to a painful stimulus. A growing
body of evidence suggests that glutamate (Glu), an exci-
tatory neurotransmitter in the central nervous system,
may play a part in the pathophysiology of FM, given that
its concentration is elevated in the insula [8], hippocam-
pus [9] and posterior cingulate cortex [10,11].
As a consequence, a number of authors have suggested
that glutamate-blocking drugs may be useful in the
treatment of FM [12]. Studies suggest that memantine
could reduce the harmful effects that result from the ex-
cessively high levels of brain glutamate found in a num-
ber of conditions, such as FM [13]. Memantine is not
believed to act by reducing levels of glutamate or by
preventing its release; rather, it is believed to reduce
glutamate’s neurotoxic effect by blocking the N-methyl-D-
aspartate (NMDA) receptor, thereby preventing the entry
of excess calcium [14]. Memantine belongs to the family
of drugs known as NMDA receptor antagonists.
NMDA receptor antagonists have neuroprotective and
analgesic properties and are widely used in clinical prac-
tice. Dextromethorphan and ketamine have demon-
strated efficacy in the treatment of pain in fibromyalgia
[15,16], although their use as long-term treatmentpresents significant difficulties [17]. The NMDA receptor
antagonist memantine is a derivative of amantadine, a drug
which has been used to treat Parkinson’s disease, spasticity,
convulsions, vascular dementia and Alzheimer's disease,
and has an excellent clinical safety record spanning more
than 20 years. It is a non-competitive open-channel blocker
that dissociates from the channel, which allows it to limit
the pathological activity of the NMDA receptor without
affecting normal synaptic activity [18].
Memantine has shown a very low incidence of side
effects in clinical trials on humans [19,20], while a re-
cent extension of trials has demonstrated the drug’s
clinical tolerability, even with prolonged use [21]. Simi-
lar low rates of adverse effects are expected with the
treatment with memantine of other disorders such as
pain [22,23], migraine [24] and fibromyalgia [25]. The
clinically approved dose of memantine for humans
starts with 5 mg/day, increasing progressively over a
period of several weeks to 20 mg/day. This progressive
dose adjustment may contribute to the drug’s lack of
side effects [19]. While this progression reduces the
NMDA receptor affinity, it contributes to the safety and
efficacy of memantine as a neuroprotective agent. How-
ever, the process also makes memantine less effective
than high-affinity antagonists (for example, ketamine)
in the treatment of chronic pain [21,26]. Nevertheless,
recent research has highlighted the efficacy of meman-
tine for the treatment of complex regional pain syn-
drome [27] and phantom limb pain [28], which suggests
that the extent of analgesia depends on the type of pain
being treated. We have carried out a preliminary open,
uncontrolled, three-month follow-up study of meman-
tine in patients with FM (EudraCT Number: 2011-
000802-23). As will be commented later on in the
discussion, in this preliminary study there was a trend
toward improvement in pain, but it was not significant,
probably due to the small sample size. Glutamate levels
did not show modifications from baseline as a lon-
ger period follow-up is usually required. After three
months, memantine-treated patients in our study
showed significant improvement in cognitive function,
symptoms of depression and global functioning (per-
sonal communication).
Aims
The primary objective is to evaluate the efficacy of
memantine in the treatment of pain (pain perception) in
patients with fibromyalgia.
The secondary objectives of this study are the following:
1) To evaluate the efficacy of memantine in the treatment
of other symptoms of fibromyalgia, such as pain threshold,
impaired cognitive function, reduced health status, an-
xiety, depression, quality of life and perceived improvement
of symptoms; 2) To evaluate the efficacy of memantine in
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trometry, in patients with fibromyalgia.Methods
Study design
Doubled-blind, multicenter, parallel randomized clinical
trial with six-month follow-up.
Seventy patients with FM will be recruited for inclu-
sion in the study upon fulfilment of selection criteria.
The patients will be randomized in two parallel groups:
a treatment group (n = 35), which will be given 20 mg
of memantine daily; a control group (n = 35), which will
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Setting and study sample (Participants)
Patients diagnosed with FM will be recruited for inclusion
in the study from primary health care centers in Zaragoza,
Spain, upon fulfilment of the following selection criteria:
a) subject (males and females) with age between 18 and 65
years; b) ability to understand Spanish; c) diagnosis of FM
performed by a rheumatology specialist according to the
American College of Rheumatology (ACR 1990) diagnos-
tic criteria; d) signing of an informed consent form; and
e) use of birth control during the study in the case of fer-
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the time of inclusion: a) be undergoing drug treatment
for fibromyalgia. In these cases, the patients will discon-
tinue treatment and go through a washout period of one
week to minimize the influence of the medication on
brain imaging. During that week, the patient may take, if
necessary, low doses of analgesics such as tramadol or
paracetamol; b) be taking memantine, or have taken
memantine during the one year prior to recruitment; c)
be suffering from an Axis I psychiatric disorder, as
diagnosed using the Structured Clinical Interview for
DSM-IV (SCID-I), that might hinder adherence to the
protocol (for example, dementia, alcohol and/or sub-
stance abuse/dependence, or schizophrenia); d) be preg-
nant or breast-feeding; e) have a hypersensitivity to the
active ingredient memantine, or to the excipients; f )
have conditions that require special precautions when
administering memantine according to the summary of
product characteristics (namely, epilepsy, circumstances
that may cause high urinary pH such as Proteus urinary
infection, renal tubular acidosis or vegetarian diet, recent
myocardial infarction, congestive heart disease and un-
controlled arterial hypertension); g) have clinically sig-
nificant and active evidence of liver or kidney disease,
hematological, respiratory, endocrine or cardiovascular
disease or disorders. However, patients with controlled
diabetes, controlled hypertension and complete or in-
complete right bundle branch block can be included in
the study; h) use drugs that may cause relevant
interactions with memantine according to the summary
of product characteristics, namely NMDA receptor
antagonists (for example, amantadine, ketamine, dex-
tromethorphan), L-Dopa, dopamine agonists and cholin-
ergic agonists; or i) use non-permitted concomitant
medication during the week prior to the first evaluation
visit or be expected to require treatment with at least
one of the drugs not permitted during the study, namely,
antidepressants (for example, duloxetine, venlafaxine,
mirtazapine, bupropion, SSRIs, and so on), analgesics
(for example, pregabalin, gabapentin, opiates, and so on)
or other drugs. During this week, patients may take
analgesics such as tramadol or paracetamol if needed,
but only sporadically to minimize the influence of the
medication on brain images.
There is currently no approved treatment with an in-
dication for the treatment of FM. In 2007, the FDA
approved pregbalin as the first drug for the treatment
of FM symptoms in the USA. This agency has sub-
sequently approved duloxetine and milnacipran for
the same indication. Although these drugs are com-
mercially available in Europe with other indications,
European regulatory authorities have recently refused
to widen their approval to include them for the treat-
ment of FM [29].A patient is to withdraw from the trial if he or she
withdraws informed consent, if the researcher feels that
he or she should withdraw from the study for reasons of
safety/efficacy or in the best interest of the patient, or if
the patient does not comply with the treatment for more
than seven consecutive days.
Intervention
Treatment group
The treatment group will receive the study drug,
memantine, in a dose of 20 mg daily for six months, in-
cluding a one-month titration period.
Control group
The control group will receive a daily dose of placebo
(coated pills with the same external appearance as the
active drug) and will take the same number of pills as
the treatment group. Administration will be through the
oral route.
This is a double-blind study. Consequently, the
patients will be randomized, and neither the patient, the
doctor nor the researcher administering questionnaires
or spectrometry will know to which group the patient
has been assigned. The recommended dose of meman
tine in adults is 20 mg once a day. To minimize adverse
effects, 20 mg doses will be reached by the following ti-
tration schema: first week, 5 mg daily; second week, 10
mg daily; third week, 15 mg daily; fourth week, 20 mg
daily.
The number of tablets in each dispensed container will
be monitored at each evaluation, keeping track of the
number the patient should have taken and how many
should remain on completion of the treatment. The
route of administration is oral, in the form of film-
coated tablets. The drug for use in the study (both
memantine pills and placebo) will be prepared, condi-
tioned and released by one qualified person according to
the principles of Good Manufacturing Practice, under
the responsibility of H Lundbeck A/S. Upon completion
of the trial, patients will continue with standard FM
treatment according to clinical practice guidelines.
Outcomes and measurements
Main outcome variables
The main efficacy variable is the improvement in the
treatment of pain, specifically pain perception. Perceived
pain will be measured by means of a visual analogue
scale (VAS) from 0 to 100. The psychometric usefulness
of VAS has been widely demonstrated [30].
Secondary variables
Secondary efficacy variables are modifications made to
values of the following clinical variables: pain threshold,
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sion, clinical improvement impression and quality of life.
Pain threshold will be measured by means of a sphyg-
momanometer, a widely used clinical test that has been
demonstrated to be useful for identifying FM patients
[31]. It is recommended that the blood pressure cuff
should be inflated in increments of approximately 10
mmHg up to 180 mmHg or to the point that pain
appears. Healthy persons tend to feel pain when the
pressure cuff is inflated to 160 mmHg or more, while
FM patients generally present pain at pressures between
100 and 110 mmHg, or even lower. Blood pressure
should be recorded to adjust for the effect of hyperten-
sion on pain threshold.
The rest of the secondary efficacy variables will be
measured by structured exams. The Cognition Mini-
Exam (MEC) will measure cognitive state. The MEC is a
structured scale that consists of 35 points grouped into
seven categories: orientation to place, orientation to
time, recall, attention and concentration, memory, lan-
guage and visual construction. In non-geriatric popu-
lations (under the age of 65) such as the sample for this
study, the threshold that suggests a ‘likely case’ of a cog-
nitive disorder is 27 points and lower. This test is the
validated Spanish-language version of the Mini-Mental
State Examination (MMSE) [32].
Health status in FM will be measured by means of the
Fibromyalgia Impact Questionnaire (FIQ). The FIQ is a
ten-item self-assessment questionnaire that measures the
health status of FM patients. The validated Spanish-
language version of this questionnaire will be used [33].
Anxiety and depression will be measured by means of the
Hospital Anxiety Depression Scale (HADS). HADS is a
scale based on self-report that was developed to detect the
presence of depression and anxiety disorders in medical
patients in primary care settings. It contains fourteen items
scored on a four-point Likert-type scale. This scale is
comprised of two subscales that separately assess depres-
sion and anxiety. The validated Spanish-language version of
this scale will be used [34]. Quality of life will be measured
by means of the EuroQol 5D (EQ5D) questionnaire. This
questionnaire is a standardized instrument used as a meas-
ure of health outcomes. It is applied to a wide range of
health conditions and treatments and provides a simple de-
scriptive profile and a single index value for health status.
The Spanish-language version of this questionnaire will be
used [35]. Perceived clinical improvement will be assessed
by the Clinical Global Impression scale (CGI).Magnetic resonance spectroscopy
Another relevant secondary efficacy variable in this
study is the level of glutamate in different regions of the
brain, namely the insula, hippocampus and posteriorcingulate cortex, as assessed by magnetic resonance
spectroscopy (MRS).
The following parameters will used for Magnetic
Resonance Spectroscopy (MRS): a T2-weighted coronal
image with repetition time (TR) = 5,350 ms, echo delay
time (ET) = 85 ms, 90° flip angle, number of excitations =
2, imaging matrix = 320 × 256, field of view (FOV) = 24
cm × 24 cm and slice thickness/distance = 5/0 mm and
taken on the plane through the internal auditory canal and
cerebral peduncle will be used to locate volumes of interest
(VOIs) (2 × 2 × 2 cm) in both hippocampi. A T1-weighted
medial sagittal image (TR = 560 ms, ET = 12 ms, 90° flip
angle, number of excitations = 1, imaging matrix = 256 ×
160, FOV = 24 cm × 24 cm, slice thickness/distance = 5/0
mm) will be obtained to locate a voxel in the posterior cin-
gulate cortex, and a parasagittal T1-weighted image will be
taken with respect to the right of the corpus callosum
plane to locate voxels on the anterior and posterior insular
regions. Proton magnetic resonance spectroscopy will be
performed with a short ET of 35 ms, a TR of 2,000 ms and
128 accumulations by means of the single-voxel spin-echo
technique, which uses selective excitation with gradient
spoiling for water suppression. Spectral acquisition will
be accomplished by means of the PROBE/PRESS (pro-
ton brain spectroscopy/point-resolved spatially localized
spectroscopy) technique. LCModel (version 6.0) user-
independent frequency domain-fitting software will be
used to quantify absolute concentrations of brain meta-
bolites in mmol/kg. Eddy current correction will be ap-
plied, and the use of the internal water signal will be the
reference from which the absolute metabolite con-
centrations will be calculated. In addition to the individual
analysis of glutamate (Glu), creatine (Cr), N-acetylaspartate
(NAA) and myo-inositol (mI) compounds, the aggregate
concentrations of the following three compound pairs will
be studied: NAA + N-acetyl-aspartyl-glutamate (NAA +
NAAG), referred to as the total phosphocholine (PCh);
Glycerophosphorylcholine (GPC), referred to as the total
Cho; and glutamate + glutamine, referred to as Glx. Abso-
lute metabolite concentrations will be considered only if
the Cramér-Rao lower bounds are lower than 20%, indicat-
ing that these metabolite concentrations can be reliably
calculated. Chemical concentrations can be extracted auto-
matically from MR spectra with well-documented time
domains, and the spectral frequency can be fitted with soft-
ware packages such as LCModel (Stephen Provencher,
Oakville, Ontario, Canada).
Table 1 shows the procedure and evaluation times of
the trial.
Sample size
The choice was made to have a sample comprising 70
subjects (n = 35 subjects in each of the two treatment
groups) because this sample size will enable us to obtain
Table 1 Procedure and evaluation times of the trial
Visit Baseline 1 month 3 months 6 months
Visit number 1 2 3 4
Recruitment & Clinical assessment




Pain assessed with sphygmomanometer X X X X
Pain assessed with Analogue Visual Scale X X X X
Cognitive function (assessed with MEC) X X X X
Global function (evaluated by FIQ) X X X X
Anxiety and depression (assessed with HADS) X X X X
Quality of life (assessed by EuroQol 5D) X X X X
Clinical Global Impression (CGI) X X X X
Neuroimage assessment
Magnetic resonance spectroscopy X X
Safety assessments
Adverse events X X X
Other study procedures
Delivery of the research drug X X X
Inventory of drug taken back and used X X X
Concomitant pharmacological treatment X X X X
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are of equal sizes at the start of the study. Smaller sam-
ple sizes have been used in the identification of signifi-
cant differences in glutamate levels in different brain
regions between FM patients and controls.
Using the results of the pilot study and taking reduc-
tion of pain (as determined using the Pain Visual
Analogue Scale and sphygmomanometry) as the primary
variables, a pre-intervention mean score of 56 (SD 14.9)
was obtained with the VAS, and 104 (SD 30.8) with
sphygmomanometry. After treatment, the means dec-
reased to 44 (SD 16.9) and 85 (SD 20.6), respectively.
Therefore, assuming a 95% confidence interval and a
power of 80%, we find that we require a sample size of
28 individuals in each group for the VAS finding and of
30 individuals in each group for the reduction measured
by sphygmomanometry. The resulting sample size that
will enable us to analyse the final variable will be 60
individuals, with 30 being assigned to each of the two
groups. Based on previous studies (personal communica-
tion), an attrition rate of 10% can be expected. There-
fore, the final number of recruited patients will be 35
patients for each arm.
Randomization, allocation and masking of study groups
Each patient will be assigned to one of the two groups
using a computer-generated random number sequence.The assignment will be carried out by an independent
person belonging to REDIAPP (Research Network on
Preventative Activities and Health Promotion) who is
not involved in the study. The random allocation se-
quence will be implemented by telephone. The sequence
will be concealed until interventions are assigned.
Patients agree to participate before the random alloca-
tion and without knowing to which treatment they will
be assigned. According to the intention-to-treat (ITT)
principle, any patients randomized and allocated to any
arm that starts the study will be included in the analysis.
Pharmacological treatment will be administered by one
psychiatrist (JGC). Study personnel conducting psycho-
logical assessments (BO, MCPY, MP, BM) will be
masked to the participants' treatment.
Statistical methods
Analysis strategy
The analysis of clinical efficacy will make use of intention-
to-treat analysis. The Last-Observation-Carried-Forward
(LOCF) method will be used for handling missing data.
An initial comparison will be made between both groups,
examining key variables to establish the groups’ baseline
comparability after randomization. To describe the quan-
titative variables, means and standard deviations will be
calculated when they fulfil normality criteria. The Chi-
squared test will be used for qualitative variables such as a
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tween clinical variables at baseline, one month, three
months and six months will be calculated using analysis of
covariance (ANCOVA) adjusted by baseline.
To study the main variable, analysis of variance will be
performed on repeated measurements, including all the
evaluations over time. The main variable (pain percep-
tion) will be taken to be a continuous variable for this
purpose. The models will include adjustments for the
baseline pain value and for any other variable that may
have shown differences in the baseline measurement.
Possible group × time interactions will be studied by
means of Mixed Factor ANOVA. Additionally, linear re-
gression models will be used to compare the differences
between the two groups for each of the evaluations over
time as compared to baseline. Similar analyses will be
performed on the other secondary clinical variables.
To analyze the differences found by the neuroimaging
test (spectrometry) taken at baseline and at six months
follow-up, Student’s t-test for paired measurements will
be calculated. The relation between neuroimaging
variables and clinical variables will be assessed by means
of Spearman’s Rho non-parametric test.
In case of lost values, a sensitivity analysis will be
made to estimate the effect of the lost values on the
results. These values will also be replaced using several
approaches, such as last recorded values and impu-
tations. Statistical analyses will be performed with the
Statistical Package for the Social Sciences (SPSS) 19.0
statistical software package (SPSS Inc., 233 South
Wacker Drive, 11th Floor, Chicago, IL 60606–6412),
with P-values below 0.05 considered significant.
Safety and monitoring
Any adverse events and serious adverse events will be
recorded and a determination will be made as to
whether any medical action required is related with the
administered drug. Any adverse event related to the
study drug will be recorded and monitored until its reso-
lution or stabilization, and the regulatory notification
process will be followed in accordance with the pertinent
legislation in force (timeframes, unmasking, and so on).
Study participants will be requested to report to the
researchers any adverse effect (serious or otherwise) that
may arise in the period between visits or any other
circumstances that may lead to their withdrawal from
the study.
Ethical aspects
Informed consent will be obtained from the participants
before they are aware of which group they are to be
included in. Before they give their consent, the patients
will be provided with a general overview of the aims and
characteristics of the study and the psychological andpharmacological intervention. They will also be in-
formed that they will be participating voluntarily and
that they can choose to withdraw at any time with the
guarantee that they will continue to receive the treat-
ment considered most appropriate by their doctor.
With regard to the potential risks of the study, data
gathering involves no risks to the subjects participating
in the study, and the neuroimaging techniques that will
be performed are non-invasive techniques that do not
place subjects in any danger. With regard to the poten-
tial benefits, if the hypothesis of the study, the patients
in the treatment group will be able to control their pain
during the course of this research. The results will be
communicated to the scientific community and to the
relevant institutions, which will lead to the expected
benefits being obtained for society and for people
diagnosed with FM. Nevertheless, there is a possibility
that there will be no benefit gained from participating in
this study.
The study follows Helsinki Convention norms with pos-
terior modifications, and the Declaration of Madrid of the
World Psychiatric Association. The Study Protocol was
approved by the Clinical Research Ethics Committee of
Aragón (June 2012) and the Medicines and Health
Products Agency of Spain (EUDRACT 2011-006244-73).
Discussion
This is the first randomized, controlled study of
memantine for the treatment of fibromyalgia. Memantine
might be expected to be useful for the treatment of FM
based on its pharmacological effects, as described in the
introduction [13,14]. In addition, our research group have
recently carried out an exploratory, uncontrolled study
with a small sample (n = 10) and a three-month follow-up
that found significant improvement of global function (as
measured by FIQ), depression (as evaluated by HADS) and
cognitive function (as assessed with MEC) in the study
patients at three-month follow-up (personal communi-
cation, Study EudraCT Number: 2011-000802-23).
However, at three-month follow-up, glutamate levels
did not decrease in any of the brain areas studied (per-
sonal communication).
Based on previous preliminary pilot studies (personal
communication) a significant improvement in key clin-
ical symptoms in fibromyalgia, such as depression, cog-
nition and global function can be expected. Cognition is
one of the most impairing symptoms in fibromyalgia
[36] and is strongly correlated with depression [37].
Cognition in these patients seems to be related to brain
morphology changes that could be improved with
memantine [38]. Depression, another frequent and quite
disabling symptom in fibromyalgia [39] is also expected
to improve with memantine due to its pharmacological
effect [40].
Olivan-Blázquez et al. Trials 2013, 14:3 Page 8 of 9
http://www.trialsjournal.com/content/14/1/3Pain, the most relevant symptom in fibromyalgia and the
main outcome of our study, was not significantly relieved
in our open, uncontrolled study (personal communication),
probably due to its small sample size. However, previous
pilot studies (26 to 28) suggest memantine is effective in
relieving pain in general. In addition, spectrometric studies
in fibromyalgia found a strong correlation between high
levels of glutamate and depression and global function, but
also with pain (10).
Treatment with memantine decreases the Glu/Cr
(glutamate/creatine) ratio in the left hippocampal region,
which may account for its anti-excitotoxic property [41].
Other studies have observed an increase in cingulate
glutamatergic turnover [42]. There is evidence from MRS
studies of other excitotoxicity-related conditions, such as
amyotrophic lateral sclerosis [43] and Huntington’s di-
sease [44], that glutamate is elevated in several brain
regions in these disorders. Thus, the decrease in
hippocampal glutamate with memantine (without changes
in NAA/Cr) could explain some of memantine’s thera-
peutic effects.
In this study, there is no clear hypothesis as to
whether memantine is able to reduce glutamate levels in
the affected brain areas, or, independent of this possibil-
ity, whether the drug will be an effective treatment for
different clinical symptoms of fibromyalgia, particularly
in the cognitive domain. It is possible that it could re-
duce glutamate without ameliorating any symptoms. Al-
ternatively, it may not reduce glutamate while improving
some target symptoms. In any case, new hypotheses as
to the aetiology of fibromyalgia, and of the origins of the
symptoms of the disease may be developed based on the
results of this preliminary research.
The main strength of the study is that this is the first
randomized controlled trial of memantine for the treat-
ment of FM. The main limitations specific to the spec-
trometric study will be the following: 1) The proportion
of grey matter/white matter and CSF within the
corresponding voxel will not be calculated, so the 1H-
MRS signals, which are produced by both grey and
white matter, will represent an amalgamation of mul-
tiple cell types. Differences in the fractions of each voxel
consisting of different tissue types may result from ana-
tomical differences associated with the conditions under
investigation. 2) Metabolites will not be quantified by
segmentation and CSF-correction, so the measured
levels of glutamate will often be contaminated in part by
glutamine. Furthermore, glutamate exists in the neuro-
transmitter pool as well as in the metabolic pool.
Trial status
Inclusion of patients commenced 15 September 2012.
Initial recruitment of patients commenced 15 September
2012.Expected finalization of patient recruitment: 31 December
2012.
Expected finalization of patient monitoring period: 30
June 2013.
Publication of results: December 2013.
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